Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

The 36-month overall survival rate was 74% in the belantamab mafodotin arm and 60% in the daratumumab arm. Belantamab ...

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

PM8002/BNT327 plus nab-paclitaxel demonstrated “clinically meaningful” activity in advanced TNBC, according to researchers.

Researchers say they have identified several factors that may be associated with inadequate ovarian function suppression.

The USPSTF has released draft recommendations for cervical cancer screening that differ somewhat from prior recommendations.

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.